Bayer launches major new stroke trial
January 27, 2015Research and Development, Sales and Marketing Bayer, Canadian Stroke Prevention Intervention Network, Population Health Research Institute, Xarelto, rivaroxaban, stroke
Bayer is enrolling more than 7,000 people in a trial to test whether its blood-thinning drug Xarelto can successfully prevent …
ABPI appoints Amgen director to innovation role
January 27, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Amgen, Bina Rawal, Virginia Acha
The Association of the British Pharmaceutical Industry (ABPI) has named Dr Virginia Acha as its new executive director of Research …
Actavis buys generics firm for £306 million
January 26, 2015Manufacturing and Production, Sales and Marketing Actavis, Allergan, Auden McKenzie, generics
Actavis is buying UK-based development and marketing firm Auden McKenzie in a deal worth up to £306 million. The move …
New drug added to generic Sovaldi licensing
January 26, 2015Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi
Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …
Shire lifted by rare disease approvals
January 26, 2015Sales and Marketing HGT-2310, Hunter syndrome, SHP609, Shire, fast track, idursulfase-IT, rare disease
Shire’s investigational drug for a rare neurological disease has been accepted into the FDA’s fast-track approval process. The drug, SHP609, …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Novartis earns EMA and FDA nods for Jakavi and Bexsero
January 26, 2015Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib
Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …
Working Life: NHS England pharma officer Dr Bruce Warner
January 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS England, Working Life, bruce warner, pharma officer
How did you find your way into your current role? I have had a very eclectic career for a pharmacist …
Cipher appoints vice president and promotes two
January 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Linda Angaritis, Peter Weiler, cipher, lynne bulgar
Cipher Pharmaceuticals has appointed Lynne Bulger as vice president of its medical and clinical affairs whilst also promoting Peter Weiler …
GSK launches Ebola Phase III trial in Liberia
January 23, 2015Research and Development, Sales and Marketing Africa, Ebola, GSK, US National Institutes of Health, WHO, Wellcome Trust, liberia, newlink
A shipment of GSK’s potential vaccine against the Ebola virus disease is on its way to Liberia ready to be …
Needle-free device shows potential in diabetes
January 23, 2015Medical Communications, Sales and Marketing Cygnus, University of California, diabetes, tattoo
A ‘tattoo-like’ ultra-thin sensor that sits on the skin has been developed that could help patients monitor their blood glucose …
Immune Pharmaceuticals appoints three
January 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Immune Pharmaceuticals, cameron durrant, elliot maza, gad berdugo
US antibody development firm Immune Pharmaceuticals has appointed Gad Berdugo (pictured) as its executive VP and chief financial officer, and …
FDA to start regulating health wearables
January 22, 2015Medical Communications, Sales and Marketing Apple, FDA, Samsung, digital, wearables
Any firms making exaggerated health claims of wearable devices face marketplace disappointment following new FDA guidelines. The FDA has released …
Sanofi Gaucher drug approved in Europe
January 22, 2015Sales and Marketing Cerdelga, Cerezyme, Gaucher, Sanofi, eliglustat, imiglucerase
The European Commission has approved Sanofi-owned Genzyme’s Cerdelga for the treatment of Gaucher disease Type 1.Designed for a condition that …
Novartis gets FDA approval for psoriasis drug
January 22, 2015Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis
The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …
UK makes £30m investment in T-Cell cancer therapy
January 22, 2015Research and Development, Sales and Marketing Autolus, Cancer, London, T cell, UK, government, oncology, syncona
The UK is making a £30 million R&D investment into a promising new type of cancer treatment and is to …
EMA launches consultation on clinical trials
January 22, 2015Research and Development, Sales and Marketing EFPIA, EMA, EU, Europe, Goldacre, alltrials, transparency
The European Medicines Agency has invited pharma to comment on its proposals to ramp up transparency in the industry and …
New chief executive for AiCuris
January 22, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AiCuris, Holger Zimmermann, Rübsamen-Schaeff
Founded in 2006 as a spin-off from Bayer, AiCuris has found a new chief executive as Helga Rübsamen-Schaeff steps aside …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Gilead and Strides partner in HIV
January 21, 2015Research and Development, Sales and Marketing Cipla, FDA, Gilead, HIV, Ranbaxy, Tenofovir Alafenamide, WHO, strides, taf
Gilead is partnering with India-based pharma firm Strides Arcolab in a licensing agreement to manufacture and distribute an HIV treatment …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
